Company: BSX
Filing Date: 2025-03-19
Form Type: DEF 14A
Source: 0000885725-25-000017
Chunk: 2

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-03-19
Form: DEF 14A
Chunk 2
---
 the long term. Boston Scientific is in an excellent position to continue increasing value for customers, employees and stockholders.

#### 2025 Proxy Statementi

#### A Letter from our CEO

#### Focused on Growth
Boston Scientific devices and therapies help physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Our category leadership strategy involves deepening our focus in those areas, as well as expanding into high-growth markets and adjacencies that complement our existing offerings. Our strategy also guides our venture capital investments –often allowing us to invest early in promising technologies – and increases our ability to take smart risks.

In 2024, we made the following business development announcements: our completed acquisition of Axonics, Inc. adds differentiated devices that treat urinary and bowel dysfunction to our robust urology portfolio and enables our expansion into sacral neuromodulation; the close of our Silk Road Medical, Inc. acquisition brings a new approach for stroke prevention and the treatment of carotid artery disease through a procedure called transcarotid artery revascularization (TCAR); and our acquisition of Cortex, Inc., completed in January 2025, complements our electrophysiology portfolio with a differentiated cardiac mapping solution to assist with complex atrial fibrillation cases. With the acquisition of SoundCath, Inc., we are developing an intracardiac echocardiography product that has the potential to simplify visualization during ablation and other cardiac procedures.

We also announced our entry into a definitive agreement to acquire Intera Oncology, Inc., whose hepatic artery infusion pump and chemotherapy drug will add to our treatments for liver cancer. And in early 2025 we announced our entry into a definitive agreement to acquire Bolt Medical, Inc., a company in which we are already a strategic investor. Upon U.S. Food and Drug Administration (FDA) approval, the addition of their intravascular lithotripsy platform can help us better serve physicians and their patients with coronary and peripheral artery disease and provides a platform for future innovation. Both acquisitions are expected to close in the first half of 2025, subject to customary closing conditions.

#### Leading a Global Transformation in AFIB
Atrial fibrillation (AF, often called “AFib”) is the most common form of abnormal heart rhythm. It is conservatively estimated to affect 38 million people worldwide, a number that’s expected to nearly triple by 2030. In treatment for AF, we are a leader in left atrial